These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 12392638)

  • 21. Imatinib mesylate acts in metastatic or unresectable gastrointestinal stromal tumor by targeting KIT receptors--a review.
    Sawaki A; Yamao K
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S44-9. PubMed ID: 15309514
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting mutant kinases in gastrointestinal stromal tumors: a paradigm for molecular therapy of other sarcomas.
    Heinrich MC; Corless CL
    Cancer Treat Res; 2004; 120():129-50. PubMed ID: 15217222
    [No Abstract]   [Full Text] [Related]  

  • 23. Disease progression following imatinib failure in gastrointestinal stromal tumors: role of surgical therapy.
    Jamali FR; Darwiche SS; El-Kinge N; Tawil A; Soweid AM
    Oncologist; 2007 Apr; 12(4):438-42. PubMed ID: 17470686
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current management of gastrointestinal stromal tumors--a comprehensive review.
    Lai EC; Lau SH; Lau WY
    Int J Surg; 2012; 10(7):334-40. PubMed ID: 22633986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Managing progressive disease in patients with GIST: factors to consider besides acquired secondary tyrosine kinase inhibitor resistance.
    Patel S
    Cancer Treat Rev; 2012 Aug; 38(5):467-72. PubMed ID: 22035971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gastrointestinal stromal tumors: diagnosis and treatment.
    Acín-Gándara D; Pereira-Pérez F; Castaño-Pascual A; Durán-Poveda M; Antequera-Pérez A; Miliani-Molina C
    Cir Cir; 2012; 80(1):44-51. PubMed ID: 22472152
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Tyrosine kinase inhibitor as a targeted therapy for GIST tumors].
    Joensuu H
    Duodecim; 2002; 118(22):2305-12. PubMed ID: 12523107
    [No Abstract]   [Full Text] [Related]  

  • 28. [Treatment progress of gastrointestinal stromal tumor].
    Ji X; Ji JF
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):292-6. PubMed ID: 23536354
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor].
    Nakajima M; Toga W
    Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):482-90. PubMed ID: 14639002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overview of issues related to imatinib therapy of advanced gastrointestinal stromal tumors: a discussion among the experts.
    Silberman S; Joensuu H
    Eur J Cancer; 2002 Sep; 38 Suppl 5():S66-9. PubMed ID: 12528775
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of imatinib mesylate (Gleevec/Glivec) in gastrointestinal stromal tumors.
    de Jong FA; Verweij J
    Expert Rev Anticancer Ther; 2003 Dec; 3(6):757-66. PubMed ID: 14686698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. F-18 FDG PET imaging in gastrointestinal stromal tumor.
    Reddy MP; Reddy P; Lilien DL
    Clin Nucl Med; 2003 Aug; 28(8):677-9. PubMed ID: 12897659
    [TBL] [Abstract][Full Text] [Related]  

  • 33. STI571: a magic bullet?
    Verweij J; Judson I; van Oosterom A
    Eur J Cancer; 2001 Oct; 37(15):1816-9. PubMed ID: 11576833
    [No Abstract]   [Full Text] [Related]  

  • 34. Combined Therapy of Gastrointestinal Stromal Tumors.
    Rutkowski P; Hompes D
    Surg Oncol Clin N Am; 2016 Oct; 25(4):735-59. PubMed ID: 27591496
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Updates on the management of gastrointestinal stromal tumors.
    Bamboat ZM; Dematteo RP
    Surg Oncol Clin N Am; 2012 Apr; 21(2):301-16. PubMed ID: 22365521
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of inoperable gastrointestinal stromal tumor (GIST) with Imatinib (Glivec, Gleevec).
    Joensuu H
    Med Klin (Munich); 2002 Jan; 97 Suppl 1():28-30. PubMed ID: 11831069
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of gastrointestinal stromal tumor: the imatinib era and beyond.
    Parikh PM; Gupta S
    Indian J Cancer; 2013; 50(1):31-40. PubMed ID: 23713042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors.
    Blanke CD; Huse DM
    J Med Econ; 2010; 13(4):681-90. PubMed ID: 21067355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improvement of psoriasis during imatinib therapy in a patient with a metastatic gastrointestinal stromal tumour.
    Miyagawa S; Fujimoto H; Ko S; Hirota S; Kitamura Y
    Br J Dermatol; 2002 Aug; 147(2):406-7. PubMed ID: 12174137
    [No Abstract]   [Full Text] [Related]  

  • 40. Complete remission of a metastatic gastrointestinal stromal tumour with the tyrosine kinase inhibitor imatinib (STI 571): effect of low dosage in an advanced tumour with exon 11 mutation.
    Högenauer C; Langner C; Lipp RW; Höfler G; Krejs GJ; Hinterleitner TA
    Eur J Gastroenterol Hepatol; 2003 Mar; 15(3):323-7. PubMed ID: 12610329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.